CTLA4 and pneumonitis: However, cancer clinical trials have documented a broad spectrum of serious adverse events associated with immune checkpoint blockade such as liver injury, thyroiditis, colitis, pneumonitis, thrombocytopenia, vasculitis and others (160), and in a murine model of CLP sepsis, anti-CTLA-4 antibody worsened survival at higher doses (37).